The core mechanism of dry eye disease is inflammation.
OBJECTIVE
The purpose of this article is to review the evidence for the hypothesis that the core mechanism of dry eye disease (DED) is inflammation, including evidence from recent basic, clinical, and translational research involving human patients, animal models, and cell cultures.


METHODS
Using the key words "dry eye + inflammation," the authors conducted a comprehensive search of the PubMed and Web of Science databases for scientific articles published in English between January 1, 1900 and August 30, 2013 on the role of inflammation in DED in cell cultures, animal models, and humans. The resulting articles were then categorized and reviewed.


RESULTS
The literature search revealed a total of 458 publications, almost all published after 1992. The percentages of original studies and review articles are 77.29% (354) and 22.71% (104), respectively. Among the original studies, the number of reports on human DED is 200 (43.7%), on animal models is 115 (25.1%), and cell cultures is 39 (8.5%). A yearly distributing plot revealed that 76% were published from 2003 to 2011, 53% from 2008 to 2012, and 11% during the first 9 months of 2013. This distribution signifies a rapidly growing awareness of the importance of inflammation in DED pathogenesis.


CONCLUSIONS
Inflammation plays a key role in the pathogenesis of DED as evidenced by research using tissue culture, animal models, and subjects with DED. Developing biomarkers for inflammation of the ocular surface will provide improved understanding of the mechanisms leading to DED, classification of the severity of DED, and objective metrics for outcome measures of treatment. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation, accompanied by alterations in both innate and adaptive immune responses. Given the underlying mechanism for DED, developing effective and safe anti-inflammatory treatments is likely to be beneficial for patients with DED.
Icahn School of Medicine at Mount Sinai (Y.W., P.A.A.), New York, NY.
Yi
Y
Wei
Penny A
PA
Asbell
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D015352:Dry Eye Syndromes / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D018384:Oxidative Stress / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology
D000893:Anti-Inflammatory Agents; D018925:Chemokines; D016207:Cytokines